BioCentury on BioBusiness,
Table: Follow-on performance
Back to the parent article
Monday, April 1, 2013
The biotech industry raised $2.3 billion via 31
follow-on deals in 1Q13. This compares to $2.1 billion via 35 deals in
1Q12. In the after-market, the range of gains and losses was -23% to +55%, but
only seven companies are now trading below their post-money valuations. The
1Q13 follow-on class is up a median of 7%.
Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) and
Celldex Therapeutics Inc. (NASDAQ:CLDX) were both up more than 50% since
their follow-ons. In March, Aegerion said it expects global net revenues of
$15-$25 million for FY13 with 250-300 patients on Juxtapid lomitapide globally
by year end. FDA approved Juxtapid in December
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]